On October 4, 2022 SomaGenics presented its novel wound healing therapeutic based on the sshRNA RNAi technology to the NIH Innovation Conference (Press release, SomaGenics, OCT 4, 2021, https://www.somagenics.com/news/2022/4/15/somagenics-presents-at-the-nih-innovation-conference-and-the-life-science-summit-company-showcase [SID1234612316]). SomaGenics also presented to investors at the Life Sciences Summit, held November 9-10, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a result of its NIH SBIR funding for the wound healing program, SomaGenics was subsidized by the NIH SEED program to present free of charge to these life sciences investor conferences and, with other such participants, received valuable coaching and feedback from the venture capital investment community.